上海润诺生物科技有限公司
- Company typePrivate
- Founded1996
- HeadquartersIrvine, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What 上海润诺生物科技有限公司 does
BioDuro (上海润诺生物科技有限公司), operating as BioDuro LLC and historically known as BioDuro-Sundia following the ~2020 merger of BioDuro and Sundia, is a global Contract Research, Development, and Manufacturing Organization (CRDMO) headquartered in Irvine, California, with primary discovery operations in Shanghai, China, and 8 global campuses worldwide. Founded in 1996 by Dr. Masood Tayebi and owned by Advent International, the company employs more than 2,000 scientists and serves approximately 1,500 active customers across biotechnology, pharmaceutical, and research institutions. Services span early-stage drug discovery through commercial manufacturing: chemistry (medicinal, peptide, parallel, computational, analytical, scale-up), biology (assay development, oncology models including PDX/CDX/humanized, pharmacology), DMPK, drug substance (process R&D, kilo/pilot API), and drug product (preformulation, formulation, ASD via HME/SDD, oral-solid manufacturing at the Irvine facility with >3 billion doses annual capacity).
The company's technology platform combines proprietary and differentiated capabilities across multiple high-value modalities, including a ChemPass-trained fragment library for FBDD with SPR-driven hit identification, a DNA-encoded peptide library with 108-channel automated synthesis enabling 10-mer+ macrocycles, a PROTAC platform with 1,000+ molecules synthesized to gram scale, an integrated ADC discovery platform, a Solution Engine for amorphous solid dispersion, and MASH/NAFLD mouse models with 12–16-week readout. The Integrated Drug Discovery (IDD) platform co-locates synthetic chemistry, biology, DMPK, and pharmacology with same-day compound handoff and automated screening cascades, marketed as compressing discovery-to-IND timelines from typical 5–7 years to 2–3 years.
BioDuro generates revenue under professional services contracts on fee-for-service (FFS) and full-time-equivalent (FTE) bases, with no publicly disclosed pricing. The go-to-market is direct enterprise field sales supplemented by inside sales and dedicated project management, supported by content marketing, on-demand webinars, virtual lab tours, and active participation in major industry conferences (EFMC, CPHI, ELRIG, Boulder Peptide). Strategic alliances extend the platform: CTI Biotechnology adds GLP toxicology and bioanalytical services, the CENRA API Solutions/CCSB joint venture adds commercial API manufacturing, and partnerships with Intangia and Atombeat integrate AI-driven target intelligence and peptide discovery. The customer base includes global biotech companies (oncology, rare disease, metabolic), mid-size and large pharmaceutical companies, and virtual or early-stage biotechs lacking in-house infrastructure.
上海润诺生物科技有限公司 firmographics
Firmographics- Name
- 上海润诺生物科技有限公司
- Legal name
- BioDuro LLC
- Website
- https://bioduro.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
上海润诺生物科技有限公司 industry classification
Industry- Product category
- Contract Drug Research and Manufacturing (CRDMO)
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro industry
- Clinical CROs (Phase I–IV)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)Preclinical CROs (Discovery/Pharmacology/DMPK)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)GMP Scale-Up, Tech Transfer & Process Validation (PPQ)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing ServicesSmall-Molecule CMC Documentation & Regulatory Support (DMF/CMC)Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
Keywords
Where 上海润诺生物科技有限公司 is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
上海润诺生物科技有限公司 business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research, Development and Manufacturing Services: BioDuro generates revenue by providing fully integrated drug discovery services (Chemistry, Biology, DMPK), drug substance manufacturing (API, RSMs, intermediates), and drug product development and manufacturing (oral solid dosages, clinical trial material) on a contract services basis. Services are offered as standalone FFS (fee-for-service) or integrated FTE (full-time equivalent) engagements. Projects span from early discovery through IND filing and commercial manufacturing.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
上海润诺生物科技有限公司 product offering
Product offeringCore offering
上海润诺生物科技有限公司 (BioDuro) is a global CRDMO providing fully integrated drug discovery, development, and manufacturing services. The company offers chemistry, biology, DMPK, pharmacology, and oncology research services alongside drug substance (API) and drug product (oral solid dose) manufacturing capabilities. Services span from early discovery through IND filing and commercial manufacturing for small and large molecule drug candidates, delivered as standalone FFS or integrated FTE engagements.
Product overview
BioDuro is a fully integrated CRDMO (Contract Research, Development, and Manufacturing Organization) offering end-to-end drug discovery, development, and manufacturing services. The company provides a comprehensive suite of services organized into Discovery (Chemistry, DMPK, Biology, Oncology, Pharmacology), Drug Substance (Process R&D, Scale Up Synthesis, Manufacturing), and Drug Product (Preformulation, Formulation Development, Manufacturing) divisions. These services are supported by specialized technology platforms including Integrated Drug Discovery (IDD), Antibody-Drug Conjugate, Peptide, PROTAC, DNA-Encoded Library (DEL), Solution Engine, MASH/NASH Mouse Models, Compound Management, and IND Enabling platforms. With 2,000+ scientists across 8 global campuses serving 1,500+ active customers, BioDuro operates as a one-stop shop to accelerate innovations from early discovery through commercialization.
Differentiator
Problem solved
Functional benefit
Brands
- Integrated Drug Discovery (IDD): A platform combining chemistry, biology, DMPK, and pharmacology services to accelerate the path from target identification to preclinical candidate selection.
- Solution Engine
- DNA-Encoded Library (DEL)
- PROTAC Platform
- NASH/MASH Mouse Models
- Compound Management
Products and services
- Chemistry Services Comprehensive chemistry capabilities for drug discovery and development including Peptide Chemistry, Medicinal Chemistry, Parallel Synthesis, Computational Chemistry, Synthetic Chemistry, Analytical Chemistry, and Scale Up Chemistry, serving biotech and pharmaceutical clients globally.
- DMPK Services Integrated Drug Metabolism and Pharmacokinetics services including In Vivo PK and TK, In Vitro ADME, Bioanalytical Service, Toxicity studies in rodents, dogs and monkeys, and Large Molecule Development and Bioanalysis for drug discovery programs.
- Discovery Biology Services Cutting-edge biology technologies supporting discovery, preclinical and translational assays including Assay Development, Biochemical Assays, Cellular Assays, Ligand Binding Assays, Protein Science, Surface Plasmon Resonance (SPR), and Biologics.
- Oncology Services Combining classic and cutting-edge in vitro and in vivo research to support drug discovery for cancer treatment, including PDX, CDX, Orthotopic Models, Syngeneic Models, Humanized Mouse Models, CAR-T and CAR-NK Mouse Models, ELISA Assays, and In Vitro Assays.
- Pharmacology Services Comprehensive pharmacology studies including Immunology & Inflammation, Metabolic, MASH Mouse Models, Respiratory, Neuroscience, and Safety Pharmacology to elucidate pharmacodynamics and mechanism of action.
- Drug Substance Services Process R&D, Scale Up Synthesis, and Drug Substance Manufacturing including Flow Chemistry, Sugar Chemistry, Peptide Chemistry, Preparative Purification, Process Safety Assessment, and Kilo/Pilot Scale API production.
- Drug Product Services Preformulation, Formulation Development, and Drug Product Manufacturing with capabilities including Hot Melt Extrusion (HME), Spray Dried Dispersion (SDD), Amorphous Solid Dispersion, Bioavailability Enhancement, and Modified Release.
- Integrated Drug Discovery (IDD) Platform Fully integrated platform combining chemistry, biology, and DMPK services to accelerate discovery from target identification to preclinical candidate selection under one roof with dedicated project management and same-day compound registration and distribution.
- Antibody-Drug Conjugate (ADC) Platform Specialized platform for antibody-drug conjugate discovery and development combining chemistry, biology, and DMPK expertise for targeted therapy development.
- Peptide Platform Comprehensive peptide chemistry platform for drug discovery including synthetic peptide synthesis, optimization, and large-scale manufacturing, delivering over 10,000 library targets with capabilities for linear, cyclic, natural and unnatural amino acid incorporation.
- PROTAC Platform Targeted protein degradation platform for PROTAC (PROteolysis Targeting Chimeras) drug discovery including chemical synthesis and in vitro biological evaluation, with over 1,000 PROTAC molecules synthesized and scaled up to gram quantities.
- DNA-Encoded Library (DEL) Platform DNA-encoded library technology for high-throughput screening and hit identification in drug discovery, featuring 108-channel automated solid-phase peptide synthesis producing oligopeptide building blocks with ~90% crude purity and enabling 10-mer+ macrocyclic peptide libraries.
- Solution Engine Platform Advanced amorphous solid dispersion (ASD) technologies for solubility and bioavailability enhancement of poorly soluble compounds, including Hot Melt Extrusion (HME), Spray Dried Dispersion (SDD), and Amorphous Solid Dispersion with 4-6 weeks in-vivo/in-vitro data turnaround.
- Compound Management Platform Integrated compound management services for efficient handling and tracking of chemical libraries during drug discovery, enabling same-day synthesis-to-biology handoff for accelerated design-synthesize-test cycles.
- IND Enabling Services Comprehensive IND filing support services including API process development, pre-formulation studies, and integrated project management for regulatory submissions across FDA, NMPA, and other global markets.
Quantifiable outcome
- Discovery-to-IND timelines reduced from 5-7 years to 2-3 years through integrated execution
- +4 more outcomes
Companies that use 上海润诺生物科技有限公司
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
上海润诺生物科技有限公司 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature10 records
上海润诺生物科技有限公司 partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, major, strategic and notable.
- Gilva TherapeuticscoreBroad collaboration spanning discovery through CMC for GV-100, a novel oral selective HDAC6 inhibitor for ADPKD. BioDuro provided API process development and production, pre-formulation studies, and integrated project management for the IND-enabling program, supporting successful advancement into Phase I clinical development in Australia. Gilva is a Taiwan-based biopharmaceutical company focused on innovative small molecule therapies for rare diseases.
- CTI Biotechnology (Suzhou) Co., Ltd.coreStrategic partnership combining BioDuro's integrated discovery (chemistry, biology, DMPK, CMC) and CTI's GLP toxicology studies and bioanalytical services. Together they offer a one-stop discovery-to-IND submission platform for global biotech and pharma clients. CTI has assisted in 143 IND approvals including 19 FDA approvals. Founded in Kunshan, Suzhou in 2011 as an investment by Centre Testing International Group (Stock Code: 300012).
- CENRA API Solutions / CCSBmajorJoint venture partnership adding commercial API manufacturing capacity. The partnership offers flexible, coordinated approach with unified quality systems, regulatory readiness, and support across small molecules, peptides, and fermentation products. Combined capabilities help programs scale from development to commercial production.
- IntangiastrategicAI-driven target intelligence partnership connecting Intangia's platform for identifying, prioritizing, and validating novel target and indication opportunities with BioDuro's integrated discovery execution capabilities. Enables workflow from 'what should we test?' to 'how should we test it?' and 'what data is needed to make a decision?' Intangia was incubated by F-Prime Capital.
- AtombeatstrategicAI-driven peptide drug discovery partnership. Atombeat is both a valued client and strategic partner of BioDuro in developing an AI-powered platform for accelerated peptide drug discovery. Founded by leading computational and medicinal chemists.
- FDA (US Food and Drug Administration)notableBioDuro's Irvine facility has partnered with FDA to showcase and provide training for FDA Consumer Safety Officers and FDA Medical Product Analysts on pharmaceutical new and novel technology, demonstrating regulatory trust and collaboration.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
上海润诺生物科技有限公司 competitors and assessment
Company assessmentDirect peers
- ChemPartner: China/US CRO and CDMO offering discovery chemistry, biology, pharmacology and manufacturing services. Comparable integrated model targeting biotech and mid-pharma with overlapping capability set.
- Pharmaron: Fully integrated drug R&D and CDMO with labs in China, UK and US providing chemistry, biology, DMPK, API and drug product services. Highly comparable integrated CRDMO model with similar cross-border operating footprint.
- WuXi AppTec: China-headquartered fully integrated CRDMO offering discovery, CMC and commercial manufacturing across small and large molecules. Closest direct competitor to BioDuro in scale, scope and customer base, particularly for US biotech seeking integrated discovery-to-IND programs.
- Asymchem Laboratories: China-based API CDMO with growing integrated discovery/CMC capabilities serving global pharma and biotech. Comparable small-molecule manufacturing and contract research services with similar geographic and operational profile.
Broad incumbents
- Lonza Group: Leading global CDMO with biologics, small molecules and cell & gene therapy manufacturing. Comparable on the drug substance and drug product manufacturing side of BioDuro's CRDMO offering.
- IQVIA: Largest global CRO with broad clinical and laboratory services including R&D solutions, bioanalytical and central labs. Competes at the upper end of the integrated services market that BioDuro targets.
- Catalent: Global CDMO with deep formulation and drug product capabilities including softgel, oral solids and biologics. Competes directly with BioDuro's drug product and bioavailability enhancement (Solution Engine) services.
- Charles River Laboratories: Large incumbent CRO/CDMO offering discovery, safety assessment, manufacturing and clinical support across North America, Europe and Asia. Overlaps with BioDuro across preclinical/CMC and competes for enterprise pharma outsourcing contracts.
- Labcorp (Labcorp Drug Development / Fortrea): Major clinical and bioanalytical lab services provider with broad CRO capabilities. Overlaps with BioDuro in central lab, bioanalytical and drug development support.
Emerging players
- Curia (formerly AMRI): Mid-size CDMO with integrated API, drug product and discovery services. Smaller in scale than BioDuro but comparable scope in small-molecule CMC and contract manufacturing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
上海润诺生物科技有限公司 social profiles
Digital presence上海润诺生物科技有限公司 financial estimates
Financial estimateRevenue estimate
Valuation estimate
上海润诺生物科技有限公司 leadership team
Management profileNumber of profiles
Profiles23 records
上海润诺生物科技有限公司 funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
上海润诺生物科技有限公司 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 上海润诺生物科技有限公司
What does 上海润诺生物科技有限公司 do?
上海润诺生物科技有限公司 (BioDuro) is a global CRDMO providing fully integrated drug discovery, development, and manufacturing services. The company offers chemistry, biology, DMPK, pharmacology, and oncology research services alongside drug substance (API) and drug product (oral solid dose) manufacturing capabilities. Services span from early discovery through IND filing and commercial manufacturing for small and large molecule drug candidates, delivered as standalone FFS or integrated FTE engagements.
Is 上海润诺生物科技有限公司 a public or private company?
上海润诺生物科技有限公司 is a private company. It is classified as private equity controlled and is currently operating.
When was 上海润诺生物科技有限公司 founded?
上海润诺生物科技有限公司 was founded in 1996. It employs 51 to 100 people.
Where is 上海润诺生物科技有限公司 based?
上海润诺生物科技有限公司 is headquartered in Irvine, United States, in the North America region.
How does 上海润诺生物科技有限公司 make money?
One revenue line is on record: contract Research, Development and Manufacturing Services.
Who are 上海润诺生物科技有限公司's main competitors?
Direct peers on record are ChemPartner, Pharmaron, WuXi AppTec and Asymchem Laboratories. Broad incumbents are Lonza Group, IQVIA, Catalent, Charles River Laboratories and Labcorp (Labcorp Drug Development / Fortrea). Curia (formerly AMRI) is listed as an emerging player.
Does 上海润诺生物科技有限公司 have an API?
No public API is recorded for 上海润诺生物科技有限公司.
What industry is 上海润诺生物科技有限公司 in?
上海润诺生物科技有限公司's product category is Contract Drug Research and Manufacturing (CRDMO). Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 54171 and its SIC code is 8731.